Fulcrum Therapeutics downgraded by Cantor Fitzgerald
$FULC
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald downgraded Fulcrum Therapeutics from Overweight to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/23/2025 | $12.00 | Market Perform → Outperform | Leerink Partners |
| 5/15/2025 | $10.00 | Neutral → Overweight | Cantor Fitzgerald |
| 9/13/2024 | $17.00 → $4.00 | Buy → Neutral | H.C. Wainwright |
| 9/12/2024 | $15.00 → $4.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 9/12/2024 | $4.00 | Outperform → Market Perform | Leerink Partners |
| 9/12/2024 | $10.00 → $2.00 | Neutral → Underperform | BofA Securities |
| 9/12/2024 | Buy → Hold | Stifel | |
| 9/12/2024 | Overweight → Neutral | Cantor Fitzgerald |